{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:58:26Z","timestamp":1787507906516,"version":"build-2736575974"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T00:00:00Z","timestamp":1473292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009457","name":"Region Zealand","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009457","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0162316","type":"journal-article","created":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T16:03:01Z","timestamp":1473350581000},"page":"e0162316","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study"],"prefix":"10.1371","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2587-8421","authenticated-orcid":true,"given":"Grith Petersen","family":"Eng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bouchelouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else Marie","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Bliddal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Bendtzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stoltenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,9,8]]},"reference":[{"issue":"22","key":"ref1","first-page":"1594","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"PE Lipsky","year":"2000","journal-title":"N Engl J Med"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"ME Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"ME Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab","volume":"54","author":"K Bendtzen","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"7","key":"ref5","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"GM Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"TR Radstake","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref7","article-title":"Key findings towards optimising adalimumab treatment: the concentration-effect curve","author":"MF Pouw","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.coph.2013.03.006","article-title":"Personalized medicine: predicting responses to therapy in patients with RA","volume":"13","author":"M van den Broek","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40744-015-0022-y","article-title":"Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate","volume":"3","author":"S Hayashi","year":"2016","journal-title":"Rheumatol Ther"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/art.30207","article-title":"Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?","volume":"63","author":"K Bendtzen","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"14","key":"ref11","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"GM Bartelds","year":"2011","journal-title":"JAMA"},{"issue":"8","key":"ref12","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis","volume":"50","author":"D Pascual-Salcedo","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective","volume":"72","author":"FB Vincent","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","volume":"72","author":"S Garces","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","article-title":"Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis","volume":"163","author":"P Charles","year":"1999","journal-title":"J Immunol"},{"issue":"Suppl 5","key":"ref16","doi-asserted-by":"crossref","first-page":"v3","DOI":"10.1093\/rheumatology\/kes113","article-title":"Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis","volume":"51","author":"E Choy","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/ar2706","article-title":"Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis","volume":"11","author":"W Hueber","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/art.27186","article-title":"Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis","volume":"62","author":"H Kokkonen","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1080\/03009740902865456","article-title":"Circulating TNFRI and TNFRII levels correlated with the disease activity score (DAS28) in rheumatoid arthritis","volume":"38","author":"Y Valle","year":"2009","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ibd.20107","article-title":"Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients","volume":"13","author":"T Spoettl","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"FC Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/rheumatology\/keq336","article-title":"Ultrasound Doppler measurements predict success of treatment with anti-TNF-α drug in patients with rheumatoid arthritis: a prospective cohort study","volume":"50","author":"K Ellegaard","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"1\u20132","key":"ref23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jim.2011.08.022","article-title":"Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists","volume":"373","author":"C Lallemand","year":"2011","journal-title":"J Immunol Methods"},{"issue":"7","key":"ref24","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2011-200975","article-title":"Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort","volume":"71","author":"JE Gottenberg","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"ref25","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1186\/ar549","article-title":"How does infliximab work in rheumatoid arthritis?","volume":"4","author":"RN Maini","year":"2002","journal-title":"Arthritis Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"675108","DOI":"10.1155\/2014\/675108","article-title":"Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-alpha and Its soluble receptors during the course of therapy with etanercept and infliximab","volume":"2014","author":"M Schulz","year":"2014","journal-title":"Biomed Res Int"},{"issue":"9","key":"ref27","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00296-008-0552-5","article-title":"Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis?","volume":"28","author":"A Ongaro","year":"2008","journal-title":"Rheumatol Int"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"G612","DOI":"10.1152\/ajpgi.90576.2008","article-title":"Infliximab and the TNF-alpha system","volume":"296","author":"EC Ebert","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","article-title":"Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions","volume":"7","author":"BJ Scallon","year":"1995","journal-title":"Cytokine"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/art.23447","article-title":"Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab","volume":"58","author":"H Mitoma","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"R105","DOI":"10.1186\/ar3386","article-title":"Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases","volume":"13","author":"E Ducourau","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1002\/art.34680","article-title":"Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity","volume":"64","author":"CL Krieckaert","year":"2012","journal-title":"Arthritis Rheum"},{"key":"ref33","article-title":"The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure","author":"SB Krintel","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s10067-013-2336-x","article-title":"Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFalpha biologics in rheumatic diseases","volume":"32","author":"CC Mok","year":"2013","journal-title":"Clin Rheumatol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1471-2474-13-184","article-title":"Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study","volume":"13","author":"A van der Maas","year":"2012","journal-title":"BMC Musculoskelet Disord"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0162316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T04:04:24Z","timestamp":1718769864000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0162316"}},"subtitle":[],"editor":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,9,8]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,9,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0162316","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,8]]}}}